454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

454O A phase (Ph) I/II trial of the CXCR2 antagonist AZD5069 in combination with enzalutamide (ENZA) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC)

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 33; p. S745
Main Authors: Guo, C., Sharp, A., Vogl, U., Colombo, I., Stathis, A., Jain, S., Chandran, K., Tiu, C., Paschalis, A., Matthews, R.E., Figueiredo, I., Rekowski, J., Yap, C., de los Dolores Fenor de la Maza, M., Turner, A., Badham, H.C., Parmar, M., Raynaud, F., Alimonti, A., de Bono, J.S.
Format: Journal Article
Language:English
Published: 01-09-2022
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
DOI:10.1016/j.annonc.2022.07.583